<p>Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 获取免费报告）首席财务官 Ian Michael Estepan 在 8 月 30 日星期五的交易中出售了 5,985 股公司股票。这些股票的平均价格为 137.36 美元，总交易额为 822,099.60 美元。此次交易后，首席财务官直接持有公司 33,946 股股份，价值约 4,662,822.56 美元。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，可通过 SEC 网站查阅。</p>
<p>获取 <strong>Sarepta Therapeutics</strong> 警报：</p>
<h2>Sarepta Therapeutics 股价下跌 0.5%</h2>
<ul>
<li>这家早期生物科技公司股票上涨 400% — 您现在应该购买吗？</li>
</ul>
<p>Sarepta Therapeutics 股票在周二的午盘交易中下跌 0.68 美元，报 135.10 美元。该公司股票的交易量为 1,186,505 股，相比平均交易量 1,346,542 股。该公司的资产负债比率为 1.05，流动比率为 3.90，速动比率为 3.19。该股市值为 127.7 亿美元，市盈率为 1,234.36，贝塔系数为 0.89。该公司的 50 天移动平均价格为 144.46 美元，200 天移动平均价格为 133.13 美元。Sarepta Therapeutics, Inc.的 12 个月最低价为 55.25 美元，最高价为 173.25 美元。</p>
<p>Sarepta Therapeutics（NASDAQ:SRPT - 获取免费报告）于 8 月 7 日星期三发布了季度财报。这家生物技术公司报告称该季度每股收益为 0.07 美元，超过了 0.01 美元的共识预期。该季度公司营收为 3.629 亿美元，低于 3.9438 亿美元的共识预期。Sarepta Therapeutics 的净利润率为 3.14%，净资产收益率为 5.32%。公司季度营收同比增长 38.9%。在去年同期，公司每股亏损为（0.27）美元。分析师预计，Sarepta Therapeutics, Inc.今年将实现 1.47 美元的每股收益。</p>
<h2>对 Sarepta Therapeutics 的对冲基金观点</h2>
<ul>
<li>Sarepta Therapeutics 股价因 FDA 批准而飙升</li>
</ul>
<p>一些对冲基金和其他机构投资者最近调整了他们对 SRPT 的持股。Capital International Investors 在去年第四季度增持了 Sarepta Therapeutics 股票 160.0%，现在持有 474.1485 万股这家生物技术公司的股票，价值 457,221,000 美元，在上个季度增持了 291.7797 万股。Farallon Capital Management LLC 在今年第一季度将其对 Sarepta Therapeutics 的持股增加了 102.8%。Farallon Capital Management LLC 现在持有 245.35 万股这家生物技术公司的股票，价值 317,630,000 美元，在上个季度增持了 124.3427 万股。挪威中央银行在去年第四季度买入了 Sarepta Therapeutics 的新头寸，价值约 80,697,000 美元。加拿大新斯科舍银行在去年第四季度买入了 Sarepta Therapeutics 的新头寸，价值约 50,990,000 美元。最后，Avoro Capital Advisors LLC 在去年第四季度将其对 Sarepta Therapeutics 的持股增加了 7.9%。Avoro Capital Advisors LLC 现在持有 434.4444 万股这家生物技术公司的股票，价值 418,935,000 美元，在上个季度增持了 31.9444 万股。86.68% 的股份由机构投资者持有。</p>
<h2>分析师的升级和降级</h2>
<p>许多股票研究分析师已经发布了关于 SRPT 股票的报告。摩根大通在 6 月 21 日星期五重申了对 Sarepta Therapeutics 股票的 “增持” 评级，并设定了 165.00 美元的目标价。Oppenheimer 将 Sarepta Therapeutics 股票的评级从 “市场表现” 升级为 “表现优异”，并为该公司设定了 180.00 美元的价格目标。摩根大通在 6 月 24 日星期一将 Sarepta Therapeutics 股票的目标价从 170.00 美元提高到 200.00 美元，并给予该公司 “表现优异” 评级。美国银行将 Sarepta Therapeutics 股票的目标价从 166.00 美元提高到 213.00 美元，并给予该公司 “买入” 评级。最后，花旗集团将 Sarepta Therapeutics 股票的目标价从 176.00 美元降至 160.00 美元，并为该公司设定 “中性” 评级。三位投资分析师对该股票给予持有评级，十六位对该公司股票给予买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “中等买入”，平均目标价为 186.22 美元。</p>
<p><strong>阅读我们对 Sarepta Therapeutics 的最新股票分析</strong></p>
<h2>关于 Sarepta Therapeutics（获取免费报告）</h2>
<p>Sarepta Therapeutics, Inc.是一家商业化阶段的生物制药公司，专注于发现和开发 RNA 靶向治疗、基因疗法和其他遗传治疗模式，用于治疗罕见疾病。该公司提供 EXONDYS 51 注射剂，用于治疗确诊为可进行外显子 51 跳跃的肌营养不良（杜欣氏肌肉营养不良）患者；VYONDYS 53，用于治疗确诊为可进行外显子 53 跳跃的杜欣氏肌肉营养不良患者；AMONDYS 45，用于治疗确诊为可进行外显子 45 跳跃的杜欣氏肌肉营养不良患者；以及 ELEVIDYS，一种基于腺相关病毒的基因疗法，用于治疗 4 至 5 岁的行走型小儿杜欣氏肌肉营养不良患者。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 Sarepta Therapeutics</li>
<li>技术指标如何帮助您找到超卖股票</li>
<li>内部人士正在购买的 3 只小市值股票</li>
<li>哪些华尔街分析师最准确？</li>
<li>分析师预测西部数据的巨大上涨 — 不要错过</li>
<li>3 只小市值股票的巨大回报潜力</li>
<li>今天市场上看涨投资者必须拥有的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过了 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ Tim Sykes 紧急交易警报：“立即采取行动”（来自 Timothy Sykes）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4"/></p>
<h2>您现在是否应该投资$1,000 在 Sarepta 医疗？</h2>
<p>在考虑 Sarepta 医疗之前，您应该听听这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单...而 Sarepta 医疗不在其中。</p>
<p>虽然 Sarepta 医疗目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Sarepta医疗

<p>萨雷普塔治疗公司首席财务官伊恩·迈克尔·埃斯特潘以平均价格为 4.36 美元出售了公司的 5985 股股票，总价值为 26,099.60 美元。交易完成后，他持有 33,946 股股票，价值约为 162,822.56 美元。该交易已在美国证券交易委员会（SEC）的申报文件中披露。公司股价在午间交易中下跌了 0.5%，至 11.10 美元</p>

<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 获取免费报告）首席财务官 Ian Michael Estepan 在 8 月 30 日星期五的交易中出售了 5,985 股公司股票。这些股票的平均价格为 137.36 美元，总交易额为 822,099.60 美元。此次交易后，首席财务官直接持有公司 33,946 股股份，价值约 4,662,822.56 美元。该交易已在向美国证券交易委员会（SEC）提交的法律文件中披露，可通过 SEC 网站查阅。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sarepta Therapeutics</strong> 警报：</p>
</div><h2>Sarepta Therapeutics Trading Down 0.5 %</h2>
<ul>
<li>This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?</li>
</ul>
<div class="lb-trans"><h2>Sarepta Therapeutics 股价下跌 0.5%</h2>
<ul>
<li>这家早期生物科技公司股票上涨 400% — 您现在应该购买吗？</li>
</ul>
</div><p>Sarepta Therapeutics stock traded down $0.68 during mid-day trading on Tuesday, hitting $135.10. The company's stock had a trading volume of 1,186,505 shares, compared to its average volume of 1,346,542. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a market cap of $12.77 billion, a price-to-earnings ratio of 1,234.36 and a beta of 0.89. The business has a 50 day moving average price of $144.46 and a 200-day moving average price of $133.13. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.</p>
<div class="lb-trans"><p>Sarepta Therapeutics 股票在周二的午盘交易中下跌 0.68 美元，报 135.10 美元。该公司股票的交易量为 1,186,505 股，相比平均交易量 1,346,542 股。该公司的资产负债比率为 1.05，流动比率为 3.90，速动比率为 3.19。该股市值为 127.7 亿美元，市盈率为 1,234.36，贝塔系数为 0.89。该公司的 50 天移动平均价格为 144.46 美元，200 天移动平均价格为 133.13 美元。Sarepta Therapeutics, Inc.的 12 个月最低价为 55.25 美元，最高价为 173.25 美元。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（NASDAQ:SRPT - 获取免费报告）于 8 月 7 日星期三发布了季度财报。这家生物技术公司报告称该季度每股收益为 0.07 美元，超过了 0.01 美元的共识预期。该季度公司营收为 3.629 亿美元，低于 3.9438 亿美元的共识预期。Sarepta Therapeutics 的净利润率为 3.14%，净资产收益率为 5.32%。公司季度营收同比增长 38.9%。在去年同期，公司每股亏损为（0.27）美元。分析师预计，Sarepta Therapeutics, Inc.今年将实现 1.47 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2>
<ul>
<li>Sarepta Therapeutics Stock Soars on FDA Approval</li>
</ul>
<div class="lb-trans"><h2>对 Sarepta Therapeutics 的对冲基金观点</h2>
<ul>
<li>Sarepta Therapeutics 股价因 FDA 批准而飙升</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company's stock valued at $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC raised its stake in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Norges Bank bought a new position in Sarepta Therapeutics in the fourth quarter worth about $80,697,000. Bank of Nova Scotia bought a new position in Sarepta Therapeutics in the fourth quarter worth about $50,990,000. Finally, Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company's stock worth $418,935,000 after buying an additional 319,444 shares in the last quarter. 86.68% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了他们对 SRPT 的持股。Capital International Investors 在去年第四季度增持了 Sarepta Therapeutics 股票 160.0%，现在持有 474.1485 万股这家生物技术公司的股票，价值 457,221,000 美元，在上个季度增持了 291.7797 万股。Farallon Capital Management LLC 在今年第一季度将其对 Sarepta Therapeutics 的持股增加了 102.8%。Farallon Capital Management LLC 现在持有 245.35 万股这家生物技术公司的股票，价值 317,630,000 美元，在上个季度增持了 124.3427 万股。挪威中央银行在去年第四季度买入了 Sarepta Therapeutics 的新头寸，价值约 80,697,000 美元。加拿大新斯科舍银行在去年第四季度买入了 Sarepta Therapeutics 的新头寸，价值约 50,990,000 美元。最后，Avoro Capital Advisors LLC 在去年第四季度将其对 Sarepta Therapeutics 的持股增加了 7.9%。Avoro Capital Advisors LLC 现在持有 434.4444 万股这家生物技术公司的股票，价值 418,935,000 美元，在上个季度增持了 31.9444 万股。86.68% 的股份由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>A number of equities research analysts have issued reports on SRPT shares. Morgan Stanley reissued an &#34;overweight&#34; rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Oppenheimer upgraded shares of Sarepta Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $180.00 price target for the company in a research report on Tuesday, May 14th. BMO Capital Markets boosted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, June 24th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, June 21st. Finally, Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $186.22.</p>
<ul>
<li>PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data</li>
</ul>
<div class="lb-trans"><p>许多股票研究分析师已经发布了关于 SRPT 股票的报告。摩根大通在 6 月 21 日星期五重申了对 Sarepta Therapeutics 股票的 “增持” 评级，并设定了 165.00 美元的目标价。Oppenheimer 将 Sarepta Therapeutics 股票的评级从 “市场表现” 升级为 “表现优异”，并为该公司设定了 180.00 美元的价格目标。摩根大通在 6 月 24 日星期一将 Sarepta Therapeutics 股票的目标价从 170.00 美元提高到 200.00 美元，并给予该公司 “表现优异” 评级。美国银行将 Sarepta Therapeutics 股票的目标价从 166.00 美元提高到 213.00 美元，并给予该公司 “买入” 评级。最后，花旗集团将 Sarepta Therapeutics 股票的目标价从 176.00 美元降至 160.00 美元，并为该公司设定 “中性” 评级。三位投资分析师对该股票给予持有评级，十六位对该公司股票给予买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “中等买入”，平均目标价为 186.22 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Sarepta Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Sarepta Therapeutics 的最新股票分析</strong></p>
</div><h2>About Sarepta Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Sarepta Therapeutics（获取免费报告）</h2>
</div><p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.是一家商业化阶段的生物制药公司，专注于发现和开发 RNA 靶向治疗、基因疗法和其他遗传治疗模式，用于治疗罕见疾病。该公司提供 EXONDYS 51 注射剂，用于治疗确诊为可进行外显子 51 跳跃的肌营养不良（杜欣氏肌肉营养不良）患者；VYONDYS 53，用于治疗确诊为可进行外显子 53 跳跃的杜欣氏肌肉营养不良患者；AMONDYS 45，用于治疗确诊为可进行外显子 45 跳跃的杜欣氏肌肉营养不良患者；以及 ELEVIDYS，一种基于腺相关病毒的基因疗法，用于治疗 4 至 5 岁的行走型小儿杜欣氏肌肉营养不良患者。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>3 Small Caps With Big Return Potential</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只股票胜过 Sarepta Therapeutics</li>
<li>技术指标如何帮助您找到超卖股票</li>
<li>内部人士正在购买的 3 只小市值股票</li>
<li>哪些华尔街分析师最准确？</li>
<li>分析师预测西部数据的巨大上涨 — 不要错过</li>
<li>3 只小市值股票的巨大回报潜力</li>
<li>今天市场上看涨投资者必须拥有的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过了 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ Tim Sykes 紧急交易警报：“立即采取行动”（来自 Timothy Sykes）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9318&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sarepta Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 在 Sarepta 医疗？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sarepta 医疗之前，您应该听听这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票清单...而 Sarepta 医疗不在其中。</p>
</div><p>While Sarepta Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sarepta 医疗目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

内幕交易：Sarepta Therapeutics, Inc.（纳斯达克股票代码：SRPT）首席财务官出售了 5,985 股股票